Novo Nordisk Acquires Licensing Rights for Hengrui’s Oral GLP-1 Drug in $2.6 Billion Deal to Tackle Obesity
Novo Nordisk has struck a significant deal to acquire the licensing rights from Hengrui Pharma for a once-weekly oral GLP-1 receptor agonist, aimed at weight management. This $2.6 billion agreement highlights the escalating competition in the pharmaceutical industry to develop innovative treatments for obesity and related metabolic disorders. The drug, which falls under the category…